Caribou Biosciences sampaikan pembaruan car-t di konferensi kesehatan

Sabtu, 16 Mei 2026

Dilaporkan oleh AI

Caribou Biosciences mendiskusikan perkembangan terapi CAR-T siap pakai dalam sebuah presentasi di Bank of America Global Healthcare Conference pada 13 Mei. Direktur Utama Rachel Haurwitz menyoroti data Fase I untuk dua program yang menargetkan limfoma dan multiple myeloma.

Perusahaan sedang mengembangkan Vispa-cel, yang menargetkan CD19 untuk limfoma, dan CB-011, yang menargetkan BCMA untuk multiple myeloma. Kedua program tersebut menerima pembaruan klinis yang signifikan pada akhir tahun lalu, dan hasil awal mendukung potensi terbaik di kelasnya, kata Haurwitz dalam sesi yang dipandu oleh analis Alec Stranahan.

CAR-T therapy achieves complete remission of three autoimmune diseases in German woman

Kamis, 09 April 2026 Dilaporkan oleh AI Gambar dihasilkan oleh AI

A 47-year-old woman bedridden with autoimmune hemolytic anemia, immune thrombocytopenia, and antiphospholipid syndrome has achieved complete remission after CAR-T cell therapy at University Hospital Erlangen in Germany. Treated by Fabian Müller after nine failed therapies, she recovered rapidly and remains healthy over a year later without medication—the first simultaneous treatment of multiple autoimmune diseases with this method.

CAR-T cell therapy shows early promise for HIV control

A small study has found that CAR-T cell therapy may offer a new way to manage HIV over the long term. The approach, already used to treat certain cancers, involves engineering a patient’s own immune cells.

Bioinvent hosts kol event on ovarian cancer therapies

Senin, 01 Juni 2026 Dilaporkan oleh AI

BioInvent International AB held a key opinion leader event on May 27, 2026, to discuss ovarian cancer treatments and TNFR2-targeted therapies.

Business

Inovio Pharmaceuticals reviews Q1 results and INO-3107 FDA status

Europe

CRIS Cancer to donate 3.6 million to Vega Oncotargets after controversy

Business

Syntara reports positive FDA feedback on amsulostat trial

Scientists develop antibodies to block widespread Epstein-Barr virus

Researchers at Fred Hutch Cancer Center have created human-like monoclonal antibodies that prevent Epstein-Barr virus (EBV) from infecting immune cells. Using mice engineered with human antibody genes, the team identified antibodies targeting viral proteins gp350 and gp42, with one fully blocking infection in lab models. The findings, published in Cell Reports Medicine, could lead to therapies for transplant patients at risk of EBV-related complications.

Oncolys president reflects on journey to world-first cancer treatment

Kamis, 18 Juni 2026 Dilaporkan oleh AI

Yasuo Urata, president of Oncolys BioPharma, reflected on the long development process after the company received approval for a viral therapy targeting esophageal cancer.

25 Juni 2026 15.16